Drug Trial Radar · NCT06271408
Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Mar 19, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Polarean, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Aerogen
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare responses to bronchodilator treatment delivered by three different aerosol delivery methods in patients with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is whether there are differences in lung ventilation following treatment with each of the three methods as measured using hyperpolarized Xe 129 with MRI. Participants will: Receive a standard dose of albuterol delivered using each of 3 aerosol delivery devices. In total, participants will receive three treatments separated by at least 1 week each. Following each treatment, participants will have inhale an MRI contrast agent called hyperpolarized Xe 129 and will have images of their lungs taken with an MRI. Researchers will compare the different lung images taken after each treatment to see if there are differences in the distribution of air in the lungs (known as ventilation).
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation SolutionDrug
Aerosolized albuterol
Vibrating Mesh NebulizerDevice
A vibrating mesh nebulizer will be used to deliver aerosolized albuterol
Metered Dose InhalerDevice
A metered dose inhaler will be used to deliver aerosolized albuterol
Jet NebulizerDevice
A jet nebulizer will be used to deliver aerosolized albuterol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ventilation Defect PercentTime frame: measured immediately postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia Sheridan Snyder Translational Fontaine Research Unit
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.